90Y-DOTA-TYR3-OCTREOTIDE ADMINISTERED TO CHILDREN WITH REFRACTORY TUMORS

90Y-DOTA-TYR3-奥曲肽治疗难治性肿瘤儿童

• 批准号: 7376989
• 负责人: M. Sue O'Dorisio
• 金额: $ 0.2万
• 依托单位: UNIVERSITY OF IOWA
• 依托单位国家: 美国
• 财政年份: 2006
• 资助国家: 美国
• 起止时间: 2006-03-01 至 2007-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7376989
• 关键词: 90Y; DOTA; TYR3; OCTREOTIDE; ADMINISTERED

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This study hypothesizes that somatostatin receptors can be exploited as a therapeutic target in the subset of neuroblastoma, medulloblastoma, the Ewing's sarcoma family of tumors and ostegenic sarcoma solid tumors that can be demonstrated to express somatostatin receptors.

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心，不一定是研究者所在机构。本研究假设，生长抑素受体可以被利用作为一个治疗目标的子集的神经母细胞瘤，髓母细胞瘤，尤文氏肉瘤家族的肿瘤和成骨肉瘤实体瘤，可以证明表达生长抑素受体。